ArticlePloS one2026
Impact of GST and TP53 gene polymorphisms on susceptibility to end stage renal disease: A case-control analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEnd-stage renal disease (ESRD) is a major global non-communicable condition associated with substantial morbidity and mortality. The current investigation aimed to report the association of GSTM1, GSTT1 genotypes and single nucleotide polymorphisms (SNPs) in GSTP1 (rs1695) and TP53 (rs1042522) genes with ESRD.
methodsClinically confirmed ESRD patients (n = 305) and healthy controls (n = 305) were enrolled from District Multan in Punjab, Pakistan, during 30-10-2023 till 28-02-2024, following their informed verbal consent. Multiplex and T-ARMS PCR based approaches were used to document the genotype at GSTs and SNPs of targeted genes and their associations with ESRD were analyzed individually as well as in combination.
resultsA significant association of absence of GSTM1, presence of GSTT1, presence of "G" polymorphic allele at rs1695 in GSTP1, and the presence of "C" polymorphic allele at rs1042522 in TP53 gene was observed with ESRD during the present study. Participants having age ranging between 26-40 years, males and smokers suffered more from ESRD.
conclusionGenetic variations in the studied GSTs, along with rs1695 in GSTP1 and rs1042522 in the TP53 gene, may influence the progression of ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.